BMO Capital Markets Has Lowered Expectations for Medpace (NASDAQ:MEDP) Stock Price

Medpace (NASDAQ:MEDP) had its price objective cut by equities research analysts at BMO Capital Markets from $460.00 to $400.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a “market perform” rating on the stock. BMO Capital Markets’ price target indicates a potential downside of 1.29% from the stock’s previous close.

Other equities research analysts have also issued reports about the company. Robert W. Baird lowered their price objective on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research note on Friday. Truist Financial decreased their price target on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and decreased their price target for the stock from $462.00 to $419.00 in a research report on Wednesday, February 18th. Mizuho set a $582.00 price target on Medpace in a research report on Wednesday, February 11th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $484.00 price target (down from $522.00) on shares of Medpace in a research report on Friday. Four research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $467.08.

Medpace Stock Performance

Shares of MEDP stock traded up $11.82 during trading hours on Friday, hitting $405.24. The company had a trading volume of 131,558 shares, compared to its average volume of 357,527. Medpace has a 12 month low of $284.10 and a 12 month high of $628.92. The firm has a market capitalization of $11.57 billion, a price-to-earnings ratio of 25.37, a PEG ratio of 2.39 and a beta of 1.39. The firm’s fifty day moving average is $470.96 and its 200 day moving average is $536.55.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 149.31% and a net margin of 17.19%.The company had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. During the same period in the prior year, the company posted $3.67 EPS. The company’s revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts expect that Medpace will post 17.05 EPS for the current fiscal year.

Insider Buying and Selling

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares in the company, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Impact Partnership Wealth LLC boosted its position in Medpace by 46.9% in the 1st quarter. Impact Partnership Wealth LLC now owns 1,426 shares of the company’s stock valued at $685,000 after buying an additional 455 shares during the last quarter. Brown Miller Wealth Management LLC lifted its stake in shares of Medpace by 8.2% in the 1st quarter. Brown Miller Wealth Management LLC now owns 741 shares of the company’s stock valued at $356,000 after purchasing an additional 56 shares during the period. 3Chopt Investment Partners LLC acquired a new position in shares of Medpace in the 1st quarter valued at $310,000. Apollon Wealth Management LLC acquired a new position in shares of Medpace in the 1st quarter valued at $259,000. Finally, Wasatch Advisors LP lifted its stake in shares of Medpace by 19.4% in the 1st quarter. Wasatch Advisors LP now owns 773,931 shares of the company’s stock valued at $371,634,000 after purchasing an additional 125,625 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Q1 results beat expectations: GAAP EPS of $4.28 topped consensus and revenue of $706.6M beat estimates, with revenue up ~26.5% YoY — showing strong near-term profitability and margin performance. Medpace (MEDP) Q1 Earnings and Revenues Beat Estimates
• Positive Sentiment: Backlog still sizeable (~$2.93B at quarter-end), which supports multi‑quarter revenue visibility even as bookings fluctuate. Medpace Holdings, Inc. Reports First Quarter 2026 Results
• Neutral Sentiment: Company maintained FY2026 guidance (EPS range $16.68–$17.50; revenue ~$2.8–$2.9B) — roughly in line with consensus on revenue but the EPS range sits near/below some street estimates, leaving mixed signals. Medpace Q1 Press Release / Guidance
• Neutral Sentiment: Robert W. Baird lowered its price target from $565 to $477 but retained an “Outperform” rating — a signal that some analysts are trimming near-term upside while remaining constructive longer term. Baird Lowers Price Target
• Negative Sentiment: Bookings weakness: net new business awards were $618.4M producing a book‑to‑bill of ~0.88x (below 1.0), raising concerns about demand/near‑term revenue sustainability and prompting the market selloff. Medpace slides as Q1 book-to-bill drops below 1
• Negative Sentiment: Leadership and legal risk: the company disclosed President Jesse Geiger’s impending retirement (CEO to reassume president duties temporarily), and multiple law firms have filed or are soliciting lead plaintiffs in securities class actions — increasing uncertainty and potential litigation costs. Class action notice / investigations

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.